DX314/CYP26B1 inhibitor

About DermaXon

DermaXon is a preclinical-stage drug discovery company utilizing a polypharmacology platform to develop novel small molecules for underserved conditions linked to the brain-skin axis, such as ichthyosis, Darier disease, pruritus, and pain. The company has secured multiple non-dilutive grants from NIH institutes and the Department of Defense, and has established a strategic partnership with AI company VantAI to accelerate two programs. While still pre-revenue, DermaXon's strategy combines targeted medicinal chemistry with academic collaborations to de-risk its pipeline aimed at genetic keratinization disorders and neuroinflammatory conditions.

Therapeutic Areas